



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07K 7/06, 7/64, A61K 38/08</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/00406</b><br><b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)  |
| <b>(21) International Application Number:</b> PCT/AU98/00490<br><b>(22) International Filing Date:</b> 25 June 1998 (25.06.98)<br><br><b>(30) Priority Data:</b><br>PO 7550 25 June 1997 (25.06.97) AU<br><br><b>(71) Applicant (for all designated States except US):</b> THE UNIVERSITY OF QUEENSLAND [AU/AU]; Brisbane, QLD 4072 (AU).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> FAIRLIE, David [AU/AU]; 73 Trevallyan Drive, Springwood, QLD 4127 (AU). TAYLOR, Stephen, Maxwell [AU/AU]; 8 Perdita Street, Bellbird Park, QLD 4300 (AU). FINCH, Angela, Monique [AU/AU]; Pioneer Drive, Narangba, QLD 4502 (AU). WONG, Allan [AU/AU]; 19 Gray Avenue, Bundaberg, QLD 4670 (AU).<br><br><b>(74) Agent:</b> GRIFFITH HACK; 509 St. Kilda Road, Melbourne, VIC 3004 (AU). |           | <b>(81) Designated States:</b> AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS  |           |  |
| <b>(57) Abstract</b><br><br>This invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The invention provides both agonists and antagonists. In preferred embodiments, the invention provides cyclic peptidic and cyclic or non-cyclic non-peptidic antagonists or agonists of C5a. The compounds of the invention are both potent and selective, and are useful in the treatment of conditions mediated by G protein-coupled receptors, especially conditions mediated by overexpression or underregulation of C5a, such as a variety of inflammatory conditions.   |           |  |